A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-12 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== 27 July === One person was killed by Russian shelling in Sumy Oblast. Ukrainian drones struck the Olenya air base in Murmansk Oblast, some 1,800 kilometers from the Ukrainian border, damaging two Tu-22M3s. Engels and Dyagilevo airfields were also attacked, along with an oil refinery in Ryazan. Russian air defence claimed to have shot down 12 drones over various oblasts. The Ukrainian 79th Air Assault Brigade again claimed to have repulsed a Russian assault east of Kurakhove, killing 23 Russian soldiers and injuring 29, as well as destroying a tank and two AFVs.
After secondary (10+), education is called DMLT; it is two years offered by vocational boards of respective states. After post-secondary education (12+), it is also called the DMLT of two years offered by vocational boards of respective states. The undergraduate degree in MLT is three or four years offered by universities. State boards of technical education (i.e., MSBTE) offer an Advanced Diploma of two years equivalent to the PGDMLT (postgraduate diploma in medical laboratory technology) offered by universities. A postgraduate degree in MLS is two years offered by universities.
== Side effects == Common side effects of silicone gel sheets include itchiness, rash, maceration of the skin, and malodor. These symptoms are generally well-tolerated and can be minimized by rinsing the area properly daily. Patients who suffer from these side effects should wash the treated area and the silicone gel sheets with mild soap since the dirt or bacteria on the sheets may irritate the scar. In tropical climates with high humidity, excessive moisture underneath the gel may lead to heat rash and uncomfortable sensations in patients.
Sources: en.wikipedia.org
As a result of its very low Lewis basicity, it is often used as a low-temperature solvent/diluent for superacids like magic acid (FSO3H/SbF5), allowing for highly reactive species like tert-butyl cation to be observed spectroscopically at low temperature (though tertiary carbocations do react with SO2 above about −30 °C, and even less reactive solvents like SO2ClF must be used at these higher temperatures).
Similarly, focal adhesions occur between the undersurface of the greater omentum and the cephalad aspect of the transverse mesocolon. These can be accessed after dividing the peritoneal fold that links the greater omentum and transverse colon. Adhesions here must be divided to separate the greater omentum off the transverse mesocolon, thus allowing access to the lesser sac proper. The fetal sigmoid colon mesentery can be visualised during routine ultrasound examination from the 12th week of pregnancy.
=== Other reactions of biochemical significance === Homocysteine can cyclize to give homocysteine thiolactone, a five-membered heterocycle. Because of this "self-looping" reaction, homocysteine-containing peptides tend to cleave themselves by reactions generating oxidative stress. Homocysteine also acts as an allosteric antagonist at Dopamine D2 receptors. It has been proposed that both homocysteine and its thiolactone may have played a significant role in the appearance of life on the early Earth.
On 13 November 2023, UNICEF reported that more than 1.5 million people in Gaza, including about 700,000 children, had been displaced. Nine days later, UNICEF reported "increasing numbers" of unaccompanied children had been identified evacuating from northern to southern Gaza by themselves. On 28 November, James Elder, a UNICEF spokesperson, stated wounded children were sheltering outdoors in car parks and gardens. By December 2023, Save the Children reported that it is likely that about 893,000 children were internally displaced in Gaza, average of 12,000 children a day forced to flee their homes, with some having to evacuate multiple times. Of the about 1.9 million displaced people in southern Gaza children make up almost 50% of the evacuees. On 9 February, Catherine Russell stated, "UNICEF is urgently calling on the parties to refrain from military escalation in Rafah Governate in Gaza where over 600,000 children and their families have been displaced – many of them more than once." As Israel began its Rafah offensive in early-May 2024, Save the Children stated, "Forcibly displacing people from Rafah while further disrupting the aid response will likely seal the fate of many children". According to UNRWA, as of 10 March 2024, there are over 187,000 individuals who have recently been displaced in Gaza. A significant number of these individuals, including numerous children, have sought refuge in UNRWA schools. Unfortunately, some of the facilities providing shelter to these displaced families, such as schools, have also suffered damage.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.